## \* bioporto

# Interim report Q1 2025

**Investor Presentation** 

BioPorto A/S

Hellerup, May 8, 2025

## **Forward-looking statements**

References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the "Company" or "BioPorto"), and any further information that may be made available in connection with the subject matter contained herein. By viewing or receiving or reading this presentation or attending any meeting where this presentation is made, you agree to be bound by the limitations, qualifications and restrictions set out below.

This presentation contains forward-looking statements. Words such as "believe", "expect", "may", "plan", "strategy", "estimate", "target" and similar expressions identify such forward-looking statements. Statements other than historical facts included in this presentation concerning our plans, objectives, goals, future events and performance are forward-looking statements. They involve risks, uncertainties and other factors, which may cause actual results, performance and achievements to differ materially from the results discussed in the forward-looking statements. These include numerous assumptions, risks and uncertainties, many of which are beyond BioPorto's control. These risks and uncertainties are described from time to time in BioPorto's Announcements and in its 2024 Annual Report under Risk Factors. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date of this presentation.

This presentation is for information purposes only and does not constitute an offer to sell or a solicitation of any offer to buy any securities issued by the Company in any jurisdiction. The information contained herein is not for distribution in the United States of America. This document does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold within the United States absent registration or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to offer or solicit an offer to buy any securities in the Company in the United States. Company securities may be sold only to qualified institutional buyers (as defined in Rule 144A under the Securities Act) in reliance on Rule 144A.

# **Highlights for Q1 2025**

- Revenue in line with expectations following a shift in bulk order timing from Q1 2025 to later in 2025
- ✓ US NGAL sales continued to increase in the first quarter and were up 20% compared to the same period last year
- In the first quarter of 2025, we re-organized the leadership team to enhance commercial operational effectiveness
- Strong momentum in the ProNephro AKI (NGAL) study for US adult use Currently we are ahead of schedule as patient enrollment are progressing fast. We maintain our goal to submit to the FDA by the end of 2026
- Strong focus on commercialization of ProNephro AKI (NGAL) in US, which is expected in the second quarter of 2025
- Successful completion of an oversubscribed direct issue of 25 million new shares at market price providing gross proceeds of DKK 33.5 million



#### TOTAL REVENUE (Q1 2025)

## **DKK 7.7 million**

A decrease of 19% compared to Q1 2024

#### ADJUSTED EBITDA (Q1 2025)

## DKK (28.1) million

Increase in headcounts and clinical study costs


## CASH POSITION (END Q1 2025) DKK 32.8 million

# Status on commercial launch and adult study



## **Strengthening of commercial platform**


- Optimized the leadership team to further strengthening our commercial platform and effectiveness
- Converting NGAL awareness to actual demand is expanding the pipeline both in the US and Europe
- Conference attendance and a high level of sales activities are generating new customers
- BioPorto's NGAL presence at 9 out of the top 10 best children's hospitals in the US
- Commercial launch of ProNehro AKI (NGAL) in the US on Roche Cobas® c501 analyzer expected in first half 2025
- Launch of ProNephro AKI (NGAL) on Beckman Coulters instruments is expected in 2026
- Plan to engage in strategic partnerships with the remaining three of the "Big 5" instrument vendors to drive commercialization of ProNephro AKI (NGAL)





# Enrollment of patients for adult ProNephro AKI (NGAL) are progressing ahead of expectations

- First patient for adult usage of ProNephro AKI (NGAL) enrolled in late 2024 at Massachusetts General Hospital well ahead of original schedule
- Patient enrollment at the 12 hospital sites are progressing ahead of expectations, keeping us ahead of schedule
- First study will determine cut-off for risk stratification of moderate to severe AKI in adults
- Enrollment of the first patient in the validation study is scheduled for Q3 2025




# Financial results Q1 2025



## Solid US revenue growth in Q1 2025 vs Q1 2024

## Revenue Q1 2025 vs Q1 2024, DKKm

Revenue per quarter, DKKm




All percentage and numerical changes are derived from the actual figures, not the rounded values shown in the figure.



# The fast-progressing clinical study impacts adjusted EBITDA loss

- Adjusted EBITDA loss of DKK 28.1m in Q1 2025 vs. DKK 15.3m in Q1 2024
- EBITDA loss increased in Q1 2025 due to costs for the adult clinical study as well as increase in headcount
- Solid cash position of DKK 32.8m by end Q1 2025

## Adjusted EBITDA loss, DKKm



Cash position, DKKm





## **Closing of second funding round in April 2025**

- On April 15, BioPorto successfully completed a direct issuance of 25,000,000 new shares at market price, providing net proceeds of 33,505,000, despite challenging financial market conditions
- This marked the second funding round in the effort to raise up to USD 20 million to build the commercial platform and fund clinical studies for ProNephro AKI (NGAL)
  - Of which DKK 115 million (approx. USD 17 million) has been secured
- The raised capital is expected to fund activities through early 2026
- Going forward we will assess funding options to optimize shareholder value by evaluating the Antibody business and explore loan facility opportunities



# Strategic roadmap and milestones towards 2029






## **Strategic milestones towards 2029**

Strategic initiatives	Targets for 2025-2026	Targets for 2027-2029
Building Commercial Platform	<ul> <li>Commercial launch of NGAL test in the US and drive usage pediatrics/young adults (US)</li> <li>Consolidate Adult usage in ROW</li> </ul>	Commercialization of ProNephro AKI (NGAL) for Adult use in US
	<ul> <li>Expand the number of FDA cleared instruments with existing partners</li> </ul>	<ul> <li>Strengthen Adult usage in ROW</li> </ul>
	Engaging in more strategic partnerships with the remaining three of the "Big 5" clinical chemistry instrument vendors	
Adult Study and NGAL label expansion (FDA/IVDR)	<ul> <li>Enrollment of the first patient in the AKI (NGAL) validation study in Q3 2025</li> </ul>	<ul> <li>NGAL Label expansion (FDA / IVDR) to increase the serviceable market</li> </ul>
	• FDA submission of ProNephro AKI (NGAL) for adults by end 2026	
	<ul> <li>Submission for the new EU regulation on in vitro medical devices (IVDR) by end 2026</li> </ul>	
Funding	<ul> <li>Target to raise up to USD 20 million of which DKK 115 million (approx. USD 17 million) has been secured</li> </ul>	
	We will assess funding options to optimize shareholder value	



## **Important future milestones**



# **Financial outlook**



## **2025 Financial outlook**


# Target total revenue in 2025Adjusted EBITDA loss in 2025Image: DKK 45-60<br/>millionImage: DKK 75-85<br/>million



- Expected revenue growth of 24-66% in 2025 driven by
  - Increased sales of NGAL products – primarily in the US
  - Revenue in 2025 will be back-end loaded
- Higher expected adjusted EBITDA loss in 2025 as a result of
  - Increased sales & marketing costs for ProNephro AKI (NGAL) in the US
  - Increased costs for clinical trials to support FDA clearance



# Aspirations of targeting USD +100 million revenue in 2029



#### Until 2026

- Total revenue of DKK 80-125m by expanding ProNephro AKI (NGAL) sales
- Cash flow positive & EBITDA neutral by end 2026 at the earliest

#### Towards 2029

DKK +700m (USD +100m) revenue and attractive profitability

### Growth will be contingent on:

- Kidney damaged biomarkers included in the KDIGO guidelines in the first part of 2026
- Entered strategic partnerships with the remaining three of the "Big 5" clinical chemistry instrument vendors, and ProNephro AKI (NGAL) commercialized on their instruments
- ProNephro AKI (NGAL) approved for adult use by FDA in 2027

\* At top-end of revenue range

\*\* DKK/USD Exchange rate app. 7.00



Contact

Niels H. Nielsen, CFO – <u>nhn@bioporto.com</u> Hanne S. Foss, Head of Investor Relations – <u>hsf@bioporto.com</u>

+45 4529 0000 | bioporto.com

